How to appeal a denied claim for step-therapy exception denied.
When a plan denies a step-therapy exception request — usually because a preferred formulary drug has been mentioned and the prescriber asked to skip it — the appeal is built around the clinical case against fail-first therapy, not re-justification of the underlying diagnosis. The governing framework is the ACA Nondiscrimination obligation at 45 C.F.R. § 147.136 (clinical criteria must not discriminate against the patient), the ERISA § 503 claims-procedure rule at 29 C.F.R. § 2560.503-1 for self-funded plans, and the per-state adverse-determination statute for the fully-insured jurisdiction.
01 · What this segment looks like
A step-therapy exception denial — and the appeal frameworks that apply to it.
The step-therapy exception segment captures a specific configuration: the patient has a clinical reason the formulary-preferred drug is wrong for them, the prescriber submits a formulary exception request or a prior authorization citing that clinical reason, and the plan denies the request on the EOB with the reason code “step-therapy exception denied.” The denial is not about whether the underlying drug is medically necessary for the diagnosis; it is about whether the patient should be required to try the preferred step first.
The appeal frameworks that apply vary by plan type. ACA marketplace plans are bound by the Nondiscrimination obligation at 45 C.F.R. § 147.136: clinical criteria, utilization management techniques, and benefit-design elements must not discriminate based on a list of protected factors, and step-therapy protocols that ignore documented prior failure on the same drug class are directly within the Nondiscrimination exception. Self-funded ERISA plans adopt the same federal Nondiscrimination rule, but the appeals procedure runs through the Department of Labor’s claims-procedure regulation at 29 C.F.R. § 2560.503-1 — full and fair review under § 503 of ERISA, a defined internal-appeal window keyed to the Adverse Benefit Determination, and the right to the claims file under (m).
A well-built step-therapy exception appeal letter cites the right Nondiscrimination framework, attaches the documentation of the prior failure or contraindication rather than re-arguing the underlying diagnosis, and frames the request as a clinical exception rather than a generic coverage dispute. The letter branches on whether the request is filed pre- (urgent, to start the prescribed therapy) or post-denial (internal appeal to overturn the EOB).
The three step-therapy shapes we see most
- 01
Continuing the same drug the patient is already on
A biologic the patient has tolerated for years, with established labs and a documented remission or stable disease score, but the plan re-prompts the patient to step through a formulary-preferred alternative they already failed years ago. The denial letter cites a step-therapy exception denial; the case for the appeal is the prior trial, the documented reaction, and the original medical record that recorded the prescriber’s switch.
- 02
Biologic with documented step failure
Rheumatology, dermatology, and gastroenterology patients who have already cycled through a preferred step-therapy agent and either did not respond or experienced adverse events. The plan denies the prescribed alternative on a step-therapy rationale; the prescriber’s documentation of the prior failure, the timing, and the labs following the trial is the heart of the appeal.
- 03
Annual re-prior-authorizations on the same drug the patient has already failed the plan's preferred alternative on, fail-first protocols that ignore documented prior failure on the same drug class, and formulary exclusions introduced mid-plan-year. The denial letter may not even mention the prior treatment history — the appeal has to re-establish it on every cycle.
Mid-plan-year formulary change
02 · Frequently asked
The Nondiscrimination, ERISA, and state frameworks that apply on a step-therapy denial.
Three questions a member typically has before drafting a step-therapy exception appeal — with the specific federal regulation and the right of review attached to each answer.
03 · Submit the step-therapy exception denial
The same formulary exception, defended with the documented prior failure.
Upload the most recent denial letter or EOB, answer the four short intake questions, and Denvow picks the Nondiscrimination framework under 45 C.F.R. § 147.136 or the ERISA § 503 procedure under 29 C.F.R. § 2560.503-1 — and the letter branches on whether you’re at the first-stage internal appeal or the second-stage external review.
Already in the intake? Pre-selected to “step-therapy exception denied” as the Segment-Denial-Reason — answer the rest and submit.
Other denial-reason pages
Denvow is template-and-tooling, not legal counsel. For denials that genuinely need litigation, an ERISA fiduciary complaint, or a state-court remedy, we recommend a licensed attorney in the relevant jurisdiction — and will say so when we see one.